Smith & Nephew PLC
LSE:SN
Net Margin
Smith & Nephew PLC
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
|
Smith & Nephew PLC
LSE:SN
|
9.5B GBP |
7%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
231.1B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
197.8B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
152.5B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
145.6B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
109.7B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
51.8B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
48.9B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.8B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42.5B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
282.1B CNY |
31%
|
Smith & Nephew PLC
Glance View
Smith & Nephew PLC, a name synonymous with innovation in the medical technology sphere, began its journey in the late 19th century in the quaint city of Kingston upon Hull, England. This humble pharmaceutical shop evolved over time into a global leader in medical devices, driven by a commitment to improve people's quality of life through pioneering healthcare solutions. Today, the company stands as a key player in three core sectors: orthopedics, advanced wound management, and sports medicine. By focusing on these specialized areas, Smith & Nephew has set itself apart, effectively addressing the complex challenges faced by aging populations and a rising demand for minimally invasive treatments. Revenue streams pour in from their innovative products, which cater to both healthcare professionals and patients worldwide. In orthopedics, they make significant headway with implants and instruments used in hip and knee replacements, essential solutions in addressing joint deterioration and injury. Their advanced wound management division tackles issues from chronic wounds to burns, supplying dressings and delivery systems designed for optimal healing. Meanwhile, the sports medicine segment contributes by offering arthroscopy and enabling technologies, crucial for athletic injury prevention and recovery. By maintaining a strong pipeline of research and development initiatives, Smith & Nephew continues to enhance its offerings, pushing the envelope in medical technology and consequently fortifying its financial foundation.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Smith & Nephew PLC's most recent financial statements, the company has Net Margin of 7.1%.
You don't have any saved screeners yet